Switching algorithms: From one immunomodulatory agent to another

Journal of Neurology

Volumn 255, Issue SUPPL. 1, 2008, Pages 44-50

  Coyle, Patricia K ^a,b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

interferon; Glatiramer acetate; Multiple sclerosis; Switching; Treatment algorithm; Treatment response

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS;

EID: 40349092805     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-1007-3     Document Type: Conference Paper

References (16)

1. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13:471-474
2. Carrá A, Onaha P, Luetic G, Burgos M, Crespo C, Deri N, Halfon J, Jacks G, Lopez A, Sinay V, Vrech C (2006) Switching of therapies in Argentina: 2-year follow-up. Mult Scler 12(Suppl 1):S94-S96
3. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H (2004) Identifying and treating patients with suboptimal responses. Neurology 63:S33-S40
4. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M (2007) Randomized, double-blind, dosecomparison study of glatiramer acetate in relapsing-remitting MS. Neurology 68:939-944
5. Gajofatto A, High A, Waubant E (2007) Switching disease-modifying therapy (DMT) after treatment failure: does it have an impact on the course of relapsing-remitting multiple sclerosis (RRMS). Neurology 68(Suppl 1):A239
6. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC (2007) Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68:977-984
7. Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS (2007) Neutralising antibodies to interferon beta in multiple sclerosis : Expert panel report. J Neurol 254:827-837
8. Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A (2006) A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 13:61-71
9. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
10. Li DK, Zhao GJ, Paty DW (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513
11. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V (2005) Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. J Neurol Sci 26(Suppl 4):S174-S178
12. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, Comabella M, Montalban X (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344-352
13. Sørensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817-827
14. Vallittu AM, Peltoniemi J, Elovaara I, Kuusisto H, Farkkila M, Multanen J, Eralinna JP (2005) The efficacy of glatiramer acetate in beta-interferon- intolerant MS patients. Acta Neurol Scand 112:234-237
15. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:14-24
16. Zwibel HL (2006) Glatiramer acetate in treatment-naive and prior interferonbeta-1b-treated multiple sclerosis patients. Acta Neurol Scand 113:378-386